How to Treat Relapsed Acute Lymphoblastic Leukemia: Transplant vs. Conventional Chemotherapy

被引:1
作者
Jain, Sandeep [1 ]
Kapoor, Gauri [1 ]
机构
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Pediat Hematol & Oncol, Rohini Sect 5, Delhi 110085, India
关键词
Relapse; ALL; Allogeneic transplant; Acute lymphoblastic leukemia; CHILDRENS-ONCOLOGY-GROUP; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; TOTAL-BODY IRRADIATION; UMBILICAL-CORD BLOOD; ISOLATED CNS RELAPSE; INTENSIVE CHEMOTHERAPY; CONDITIONING REGIMENS; PREPARATIVE REGIMENS; RANDOMIZED-TRIAL;
D O I
10.1007/s12098-013-1036-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Management of relapsed acute lymphoblastic leukemia (ALL) is challenging and far from satisfactory. The treatment approaches are often varied and controversial. The duration of first remission, site of relapse, immunophenotypic and molecular characteristics of relapsed disease and response to therapy influence treatment outcome. There are three main therapeutic options i.e., chemotherapy alone, induction chemotherapy followed by HLA matched allogeneic transplant and palliation. These may be chosen based on the above mentioned factors. The response to therapy may be evaluated morphologically or by minimal residual disease (MRD). Persistence of MRD, as assessed by molecular techniques or through flowcytometry, clearly influences prognosis in children with relapsed ALL. It not only helps in identifying the subset of patients likely to benefit from allogeneic bone marrow transplant (ABMT) but also in determining the timing of transplant. Patients with non-T phenotype, with late relapsing disease and good response to re-induction therapy have been shown to do equally well with chemotherapy alone. On the other hand patients with early relapse and poor initial response are selected for ABMT. With the improvement in supportive care, better selection of HLA match donors and better immunosuppressive therapies, transplant related mortality has decreased considerably. Despite all of these overall salvage rates are still poor and novel agents are being tested in various trials to establish their role in relapsed ALL therapy.
引用
收藏
页码:846 / 852
页数:7
相关论文
共 35 条
[1]   Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group [J].
Bader, Peter ;
Kreyenberg, Hermann ;
Henze, Guenter H. R. ;
Eckert, Cornelia ;
Reising, Miriam ;
Willasch, Andre ;
Barth, Andrea ;
Borkhardt, Arndt ;
Peters, Christina ;
Handgretinger, Rupert ;
Sykora, Karl-Walter ;
Holter, Wolfgang ;
Kabisch, Hartmut ;
Klingebiel, Thomas ;
von Stackelberg, Arend .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :377-384
[2]   Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: A pediatric oncology group study [J].
Barredo, Julio C. ;
Devidas, Meenakshi ;
Lauer, Stephen J. ;
Billett, Amy ;
Marymont, MaryAnne ;
Pullen, Jeanette ;
Camitta, Bruce ;
Winick, Naomi ;
Carroll, William ;
Ritchey, A. Kim .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3142-3149
[3]   Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor [J].
Bleakley, M ;
Shaw, PJ ;
Nielsen, JM .
BONE MARROW TRANSPLANTATION, 2002, 30 (01) :1-7
[4]   Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: A single-institution study [J].
Boulad, F ;
Steinherz, P ;
Reyes, B ;
Heller, G ;
Gillio, AP ;
Small, TN ;
Brochstein, JA ;
Kernan, NA ;
O'Reilly, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :197-207
[5]   Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia:: A Pediatric Blood and Marrow Transplant Consortium study [J].
Bunin, N ;
Aplenc, R ;
Kamani, N ;
Shaw, K ;
Cnaan, A ;
Simms, S .
BONE MARROW TRANSPLANTATION, 2003, 32 (06) :543-548
[6]   Approval summary: Nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma [J].
Cohen, Martin H. ;
Johnson, John R. ;
Massie, Tristan ;
Sridhara, Rajeshwari ;
McGuinn, W. David, Jr. ;
Abraham, Sophia ;
Booth, Brian P. ;
Goheer, M. Anwar ;
Morse, David ;
Chen, Xiao H. ;
Chidambaram, Nallaperumal ;
Kenna, Leslie ;
Gobburu, Jogarao V. ;
Justice, Robert ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2006, 12 (18) :5329-5335
[7]   Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia [J].
Davies, SM ;
Ramsay, NKC ;
Klein, JP ;
Weisdorf, DJ ;
Bolwell, B ;
Cahn, JY ;
Camitta, BM ;
Gale, RP ;
Giralt, S ;
Heilmann, C ;
Henslee-Downey, PJ ;
Herzig, RH ;
Hutchinson, R ;
Keating, A ;
Lazarus, HM ;
Milone, GA ;
Neudorf, S ;
Perez, WS ;
Powles, RL ;
Prentice, HG ;
Schiller, G ;
Socié, G ;
Vowels, M ;
Wiley, J ;
Yeager, A ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :340-347
[8]   Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group [J].
Dunsmore, Kimberly P. ;
Devidas, Meenakshi ;
Linda, Stephen B. ;
Borowitz, Michael J. ;
Winick, Naomi ;
Hunger, Stephen P. ;
Carroll, William L. ;
Camitta, Bruce M. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2753-2759
[9]   Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research [J].
Eapen, M ;
Raetz, E ;
Zhang, MJ ;
Muehlenbein, C ;
Devidas, M ;
Abshire, T ;
Billett, A ;
Homans, A ;
Camitta, B ;
Carroll, WL ;
Davies, SM .
BLOOD, 2006, 107 (12) :4961-4967
[10]   Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy:: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Miinster Group 87 [J].
Einsiedel, HG ;
von Stackelberg, A ;
Hartmann, R ;
Fengler, R ;
Schrappe, M ;
Janka-Schaub, G ;
Mann, G ;
Hählen, K ;
Göbel, U ;
Klingebiel, T ;
Ludwig, WD ;
Henze, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7942-7950